Stalleicken D, Kuntze U, Schmid B, Hiebl R, Ring J, Michaelis K
ISIS Pharma GmbH, Zwickau, Germany.
Arzneimittelforschung. 1997 Apr;47(4):347-52.
Up to now, there has been no data available on the pharmacokinetics of pentaerythrityl tetranitrate (PETN, CAS 78-11-5) and its metabolites, pentaerythrityl-trinitrate (PE-tri-N), pentaerythrityl-dinitrate (PE-di-N), pentaerythrityl-mononitrate (PE-mono-N) in human plasma. Therefore, in order to determine PETN and its metabolites in plasma sensitive and highly selective GC/MS methods had to be developed and validated. PETN and its metabolite PE-tri-N were validated in the concentration range 50 pg/ml to 10 ng/ml. Isosorbide dinitrate (ISDN) was used as the internal standard and the analytes were extracted with dichloromethane from the plasma. The mass spectrometric tests were carried out using chemical ionization in the negative mode (NlCl) with the application of ammonia as a reagent gas. The nitrate ion m/z 62 was determined in the analytes and internal standard. The accuracy of the mean of the quality control samples during the three days (between days) was between 100 and 110% (PETN), as well as 90 and 106% (PE-tri-N). After an oral application of 100 mg PETN in a pilot study, unchanged PETN and PE-tri-N was measured in plasma. Both metabolites PE-di-N and PE-mono-N were validated at the concentration range of 0.25 ng/ml to 25 ng/ml plasma. After extraction, these analytes were derivatized with BSTFA (N,O-bis[trimethylsilyl]trifluoro-acetamide). The applied internal standard was isosorbide-5-mononitrate (IS-5-MN). The mass spectrometric tests were carried out in the same manner as for PETN and PE-tri-N with chemical ionization in the NlCl mode. The detected masses were m/z 324 for PE-di-N, m/z 351 for PE-mono-N and m/z 217 for IS-5-MN. The accuracy of the mean of the quality control samples during 5 days were between 104 and 107% (PE-di-N) and 102 and 106% (PE-mono-N). The maximum concentration of these analytes in the subject samples were on the average all over 5 ng/ml plasma after the oral administration of 100 mg PETN.
到目前为止,关于季戊四醇四硝酸酯(PETN,化学物质登记号78-11-5)及其代谢产物季戊四醇三硝酸酯(PE-tri-N)、季戊四醇二硝酸酯(PE-di-N)、季戊四醇一硝酸酯(PE-mono-N)在人体血浆中的药代动力学尚无可用数据。因此,为了灵敏且高选择性地测定血浆中的PETN及其代谢产物,必须开发并验证气相色谱/质谱联用(GC/MS)方法。PETN及其代谢产物PE-tri-N在50 pg/ml至10 ng/ml的浓度范围内进行了验证。使用硝酸异山梨酯(ISDN)作为内标,用二氯甲烷从血浆中萃取分析物。质谱测试采用负模式(NlCl)下的化学电离,以氨气作为反应气。在分析物和内标中测定了硝酸根离子m/z 62。三天内(日间)质量控制样品均值的准确度在100%至110%(PETN)以及90%至106%(PE-tri-N)之间。在一项初步研究中口服100 mg PETN后,在血浆中检测到了未变化的PETN和PE-tri-N。两种代谢产物PE-di-N和PE-mono-N在血浆浓度范围0.25 ng/ml至25 ng/ml内进行了验证。萃取后,这些分析物用BSTFA(N,O-双[三甲基硅基]三氟乙酰胺)进行衍生化。所应用的内标为5-单硝酸异山梨酯(IS-5-MN)。质谱测试以与PETN和PE-tri-N相同的方式进行,采用NlCl模式下的化学电离。检测到的质量数分别为PE-di-N的m/z 324、PE-mono-N的m/z 351和IS-5-MN的m/z 217。五天内质量控制样品均值的准确度在104%至107%(PE-di-N)和102%至106%(PE-mono-N)之间。口服100 mg PETN后,受试者样品中这些分析物的最大浓度平均均超过5 ng/ml血浆。